UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 12b-25

Commission File Number: 001-39555

		NOTIFICATION OF LAT	E FILING
☐ Form 10-K ☐ Form 10-D	☐ Form 20-F ☐ Form N-SAR	☐ Form 11-K ☐ Form N-CSR	⊠ Form 10-Q
For Period Ended: N	March 31, 2024		
 □ Transition Report on Form 10-K □ Transition Report on Form 20-F □ Transition Report on Form 11-K 		☐ Transition Report on Form 10-Q☐ Transition Report on Form N-S/	
For the Transition F	Period Ended:		
Nothing in this form	n shall be construed to imply	that the Commission has verified any in	formation contained herein.
If the notification re	elates to a portion of the filin	ag checked above, identify the Item(s) to	which the notification relates:
		PART I REGISTRANT INFORM	ATION
Full name of registrant		Greenwich LifeSciences, Inc.	
Former name if applicable Address of principal executive office City, state and zip code		3992 Bluebonnet Dr, Building 14 Stafford, TX 77477	
		PART II RULE 12b-25 (b) ANI	D (c)
If the subject repor completed. (Check box if app		t unreasonable effort or expense and the	e registrant seeks relief pursuant to Rule 12b-25 (b), the following should be
(b) The subject annual the 15 th calendar da portion thereof, will	report, semi-annual report, t ay following the prescribed I be filed on or before the fif		K or Form N-SAR or Form N-CSR, or portion thereof will be filed on or before r transition report on Form 10-Q or subject distribution report on Form 10-D, o due date; and
		PART III NARRATIVE	
State below in reason prescribed time period.	onable detail the reasons wh	y Form 10-K, 11-K, 20-F, 10-Q, N-SAR	, N-CSR, or the transition report portion thereof, could not be filed within the
Report") within the prescribe	ed time period without unre		on Form 10-QK for the three months ended March 31, 2024 (the "Quarterly my currently expects to file the Quarterly Report by May 20, 2024, within the ct of 1934, as amended.
			024. The new auditors needed some time to begin the year end audit and the al time with respect to the Form 10-K, this prevented them from starting the

PART IV OTHER INFORMATION

review for the March 31, 2024 Form 10-Q on a timely basis which is the reason why the Company is filing the Form 12b-25.

(1) Name and telephone number of person to contact in regard to this notification

Snehal Patel	(832)	819-3232
(Name)	(Area Code)	(Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s).

 \boxtimes Yes \square No

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

 \square Yes \boxtimes No

If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be

\mathbf{R} Greenwich LifeSciences, Inc. (Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

/s/ Snehal Patel
Snehal Patel Dated: May 15, 2024

By:

Chief Executive Officer Title: